140 related articles for article (PubMed ID: 18952478)
1. Liver toxicity of TNFalpha antagonists.
Dominique L
Joint Bone Spine; 2008 Dec; 75(6):636-8. PubMed ID: 18952478
[No Abstract] [Full Text] [Related]
2. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M; Bonkovsky HL; Kum C; Davern T; Hayashi PH; Kleiner DE; Serrano J; Rochon J; Fontana RJ; Bonacini M;
Clin Gastroenterol Hepatol; 2013 May; 11(5):558-564.e3. PubMed ID: 23333219
[TBL] [Abstract][Full Text] [Related]
3. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.
Thiéfin G; Morelet A; Heurgué A; Diebold MD; Eschard JP
Joint Bone Spine; 2008 Dec; 75(6):737-9. PubMed ID: 18693125
[TBL] [Abstract][Full Text] [Related]
4. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
5. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept.
Carlsen KM; Riis L; Madsen OR
Clin Rheumatol; 2009 Aug; 28(8):1001-3. PubMed ID: 19370307
[TBL] [Abstract][Full Text] [Related]
6. Granulomatous hepatitis associated with etanercept therapy.
Farah M; Al Rashidi A; Owen DA; Yoshida EM; Reid GD
J Rheumatol; 2008 Feb; 35(2):349-51. PubMed ID: 18260163
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
Ortonne JP
Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346
[No Abstract] [Full Text] [Related]
8. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
Kluger N; Girard C; Guillot B; Bessis D
Acta Derm Venereol; 2009; 89(3):332-4. PubMed ID: 19479148
[No Abstract] [Full Text] [Related]
9. [Proper usage of biologics for treatment of rheumatoid arthritis].
Murayama M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):894-8. PubMed ID: 19469085
[No Abstract] [Full Text] [Related]
10. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
Björnsson ES; Gunnarsson BI; Gröndal G; Jonasson JG; Einarsdottir R; Ludviksson BR; Gudbjörnsson B; Olafsson S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):602-8. PubMed ID: 25131534
[TBL] [Abstract][Full Text] [Related]
11. Side effects of anti-TNF therapy: current knowledge.
Antoni C; Braun J
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S152-7. PubMed ID: 12463468
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.
El Mansouri L; Couchouron T; Le Roux G; Dugast C; Burtin F; Albert JD; Perdriger A; Hassouni NH; Chalès G
Joint Bone Spine; 2009 Jul; 76(4):421-3. PubMed ID: 19457692
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor inhibitors: maximizing patient safety.
Cairns AP; Taggart AJ
Rheumatology (Oxford); 2003 Jan; 42(1):188-9. PubMed ID: 12509638
[No Abstract] [Full Text] [Related]
14. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
15. Effect of TNF antagonists on the T-lymphocyte response.
Emilie D
Joint Bone Spine; 2007 Dec; 74(6):558-9. PubMed ID: 17950650
[No Abstract] [Full Text] [Related]
16. [What is the risk of malignancies associated with anti-TNF therapy?].
Jonville-Béra AP; Lorette G
Presse Med; 2009 Sep; 38(9):1209-10. PubMed ID: 19324517
[No Abstract] [Full Text] [Related]
17. Summaries for patients. Tumor necrosis factor antagonists and heart failure.
Ann Intern Med; 2003 May; 138(10):I48. PubMed ID: 12755581
[No Abstract] [Full Text] [Related]
18. New biologic therapies for psoriatic disease.
Bohjanen KA; Prawer SE
Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
[TBL] [Abstract][Full Text] [Related]
19. [Are there differences among anti-TNFα biological drugs?].
Valesini G
Reumatismo; 2005; 57(4 Suppl):1-2. PubMed ID: 16385348
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Hyrich KL; Silman AJ; Watson KD; Symmons DP
Ann Rheum Dis; 2004 Dec; 63(12):1538-43. PubMed ID: 15242866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
